India’s struggle with TB drug shortages: Gross mismanagement

Source: The post India’s struggle with TB drug shortages has been created, based on the article “Gross mismanagement: India is falling behind in efforts to control tuberculosis” published in “The Hindu” on 10th April 2024.

UPSC Syllabus Topic: GS Paper 2-governance-Issues relating to development and management of Social Sector/Services relating to Health.

News: The article discusses India’s struggle with TB drug shortages. Despite plans to eliminate TB by 2025, there are ongoing issues with drug availability. The government’s management of the TB program is criticized, and the burden on patients to obtain medicines is highlighted. India’s struggle with TB Drug Shortages

For details information on Eliminating tuberculosis (TB) in India by 2025 read here

What is the current situation with TB in India?

India is facing a TB drug shortage, affecting both drug-sensitive and multi-drug-resistant TB (MDR-TB).

India’s TB drug supply disruption started in 2022 with drug-sensitive medicines and escalated to include MDR-TB drugs, lasting nearly a year.

For example, a severe shortage of critical MDR-TB drugs occurred seven months ago. In September 2021, India experienced a stockout of the MDR-TB drug Delamanid.

Despite being a significant producer of these drugs, India’s management of the TB program has been inadequate.

How has the government responded?

The government renamed the National TB Control Programme to the National TB Elimination Programme, aligning with the goal to eliminate TB by 2025.

Despite the renaming, fundamental issues like drug availability haven’t been effectively addressed.

A Health Ministry circular dated March 18, 2024, acknowledged potential delays in drug supply due to “unforeseen and extraneous circumstances.”

States have been permitted to procure TB drugs locally as a temporary measure for three months.

In cases where district health facilities can’t provide free drugs, patients may be reimbursed for medicines they purchase, indicating a reliance on patients to manage their own treatment in emergencies.

What are the challenges for patients?

The frequent drug shortages force patients to either wait for medication or buy it themselves. Many TB patients in India come from poor socioeconomic backgrounds, making it hard to afford medicines.

The government’s solution of reimbursing patients who buy their own drugs is problematic, as it assumes patients can initially afford the drugs. This approach adds financial strain to patients already struggling with health issues.

Questions for practice:

Evaluate the effectiveness of the Indian government’s response to the TB drug shortage crisis and its impact on patients.